Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma

Share :
Published: 9 Jul 2024
Views: 10
Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

Dr Jeremy Abramson talks to ecancer about his study STARGLO.

The STARGLO Phase III trial compared Glofitamab combined with GemOx (Glofit-GemOx) versus rituximab combined with GemOx (R-GemOx) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who were ineligible for autologous stem cell transplant.

The study found that Glofit-GemOx significantly improved overall survival (OS), progression-free survival (PFS), and complete remission (CR) rates compared to R-GemOx.

Despite higher rates of adverse events, the safety profile was consistent with known risks.

Glofitamab is the first CD20 bispecific antibody to show a survival benefit in a randomised Phase III trial for DLBCL.